Daniel Von Hoff

From Wikipedia, the free encyclopedia
Jump to: navigation, search

Daniel D. Von Hoff is the physician in chief and director of translational research at Translational Genomics Research Institute (TGen). He is also a professor of medicine at the Mayo Clinic and medical director of research as well as chief scientific officer at US Oncology. He is most notable for his work in targeted therapies for the treatment of cancer.[1] He led the development of gemcitabine,[2] and has several drugs in development.

Education[edit]

Von Hoff received his bachelors from Carroll College[disambiguation needed], and his MD from Columbia University College of Physicians and Surgeons in 1973.[3] He did a residency in internal medicine at UC San Francisco, followed by a fellowship in oncology at the National Cancer Institute.

Career[edit]

After his fellowship, Von Hoff joined the faculty at University of Texas Health Science Center, San Antonio (UTHSCSA) as a professor of medicine and cellular and structural biology. In 1989, he became the founding director of UTHSCSA's Institute for Drug Development at the Cancer Therapy and Research Center. He later became the director of the cancer center and professor of medicine at the University of Arizona.[4][5]

Von Hoff has been part of more than 200 clinical trials.[6] Some of the drugs he has been involved in the development of include mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, and vismodegib.[7]

Awards[edit]

References[edit]